Samsung Biologics plans to list in S.Korea in 2016

SEOUL, April 28 (Reuters) - Samsung Biologics Co Ltd, the

biopharmaceutical contract manufacturing affiliate of Samsung

Group, said on Thursday that it decided to pursue an

initial public offering in South Korea in 2016.

Read more